Loading stock data…
RGNX
$6.34+0.21 (+3.43%)
After Hours$6.34+0.00 (+0.00%)· Last close Jun 9
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
REGENXBIO Inc. in the Healthcare sector is trading at $6.34 with a market capitalization of $346M. Wall Street consensus targets $23.82 (11 analysts), implying a +275.7% move over the next 12 months. The stock is currently near its 52-week low of $5.46, remaining 39.1% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +275.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$6.34
Potential Downside
0%
Whystock Fair Value$6.34
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Buy
Mean target$23.82+275.7%
Range$10.00 – $50.00
Fundamentals
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$345.86M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.12
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1375.64%
Volume
Today's trading volume
1.18M
Recent News
Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage Care
OCGN is advancing gene-agnostic eye therapies across retinal diseases, with key trial data and regulatory milestones approaching in 2026 and 2027.
How The REGENXBIO (RGNX) Investment Story Is Evolving Without New Analyst Commentary
REGENXBIO’s latest analyst update keeps the existing price targets unchanged, signaling no new moves on that front. With no fresh commentary from covering analysts, the focus is squarely on how the story could shift as new data points or corporate updates emerge. Read on to see how to track those developments and assess what they might mean for your own view of the stock over time. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to...
Before Buying Regenxbio Inc (RGNX) Stock, Check Out the Cash Runway
Regenxbio Inc (NASDAQ:RGNX) is one of the best gene therapy stocks to buy in 2026. On May 14, Regenxbio reported its Q1 2026 financial results and provided operational updates. The company exited the quarter with $150.5 million in cash. The management expects the cash balance to be enough to fund operations into early 2027. Regenxbio […]
Regenxbio (RGNX) Q1 2026 Earnings Transcript
Earlier this morning, REGENXBIO released pivotal top line data from the AFFINITY DUCHENNE trial of RGX-2026 as well as financial and operating results for the first quarter ended March 31, 2026. Today's webcast will include forward-looking statements regarding our financial outlook in addition to regulatory and product development plans. Any such forward-looking statements are not guarantees of future performance and involve certain risks and uncertainties.
Regenxbio Inc (RGNX) Q1 2026 Earnings Call Highlights: Promising RGX-202 Results and Path to ...
Regenxbio Inc (RGNX) reports significant progress in its Duchenne muscular dystrophy gene therapy trial, with potential for accelerated FDA approval in 2027.